Facing Delays in Orders, Lion Tightens Belt by Slashing Staff, Reshuffling Execs | GenomeWeb

Lion Bioscience’s newly appointed supervisory board, led by former CEO Friedrich von Bohlen, held its first meeting on Nov. 11. Within a week, the company confirmed its plan to delist its shares from the Nasdaq exchange, rearranged an executive management team that had been in place for just over a month, and announced plans to lay off around half of its remaining staff over the next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.